Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Cytosorbents ( (CTSO) ) has issued an update.
CytoSorbents Corporation announced the rescheduling of its fourth quarter and full year 2024 earnings release to March 31, 2025, to allow additional time for the completion of its annual audit. The company reaffirmed its preliminary financial results, expecting significant growth in product revenue and gross margin compared to the previous year. The company’s marketing applications for DrugSorb-ATR are under review by the U.S. FDA and Health Canada, with decisions anticipated in 2025. Additionally, CytoSorbents raised $7.85 million in the first quarter of 2025, enhancing its cash position as it continues to develop its innovative blood purification technologies.
More about Cytosorbents
CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The company’s proprietary technologies use biocompatible, highly porous polymer beads to remove toxic substances from blood and other bodily fluids. CytoSorbents’ products are used in various applications, including the removal of blood thinners during cardiothoracic surgery and inflammatory agents in critical illnesses. Their lead product, CytoSorb, is approved in the European Union and distributed in 76 countries, with FDA Emergency Use Authorization in the United States for COVID-19 patients.
YTD Price Performance: 22.83%
Average Trading Volume: 263,608
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $60.31M
See more data about CTSO stock on TipRanks’ Stock Analysis page.